Abstract #9094

Quality of Life (QoL) of OSE2101 in HLA-A2+ Non-Small Cell Lung Cancer (NSCLC) patients after failure to immune checkpoint inhibitors (IO): Final data of Phase 3 Atalante-1 randomized trial

2022 ASCO ANNUAL MEETING

Authors: B. Besse[1], R.G Campelo[2], M. Cobo-Dols[3], E.A. Quoix[4], A. Madroszyk[5], E. Felip[6], F. Cappuzzo[7], F. Denis[8], W. Hilgers[9], G. Romano[10], D. Debieuvre[11], D. Galetta[12], E. Baldini[13], S. Viteri[14], M.D. Phan[15], W. Schuette[16], A. Zer[17], B. Vasseur[18], R. Dziadziuszko[19], G. Giaccone[20]

[1]Gustave Roussy Institute, Villejuif; [2]Hospital Universitario A Coruña; [3]Hospital Universitario Regional Málaga; [4]Hôpitaux Universitaires de Strasbourg-Nouvel Hôpital Civil; [5]Institut Paoli-Calmettes, Marseille; [6]Vall d'Hebron University Hospital, Institute of Oncology, Barcelona; [7]Istituto Nazionale Tumori "Regina Elena", Rome; [8]Institut Inter-Regional de Cancérologie Jean Bernard-Elsan, Le Mans; [9]Institut Sainte Catherine, Avignon; [10]Oncologia Medica, Lecce; [11]Groupe Hospitalier de la région Mulhouse Sud Alsace; [12]IRCCS Istituto Tumori Giovanni Paolo II, Bari; [13]Ospedale San Luca, Lucca; [14]Instituto Oncológico Dr. Rosell, Hospital Universitario Dexeus, Grupo Quironsalud Cancer Center, Barcelona; [15]University of Oklahoma Health Sciences Center; [16]Martha-Maria City Hospital Halle-Doelau; [17]Davidoff Cancer Center, Rabin Medical Center, Petah Tikva; [18]OSE Immunotherapeutics, Paris; [19]Medical University of Gdańsk; [20]Weill-Cornell Medical Center, New York

Background:

- OSE2101 (Tedopi) is a **cancer vaccine increasing median overall survival (OS) by 3.6 months with HR of 0.59 (p=0.017) versus chemotherapy (**docetaxel or pemetrexed) in **HLA-A2+ EGFR and ALK negative in NSCLC patients with IO secondary resistance after sequential CT-IO** (predefined Population of Interest (PoI) of 118 patients)**[1].** HR for OS in overall population of primary or secondary resistance after sequential or concomitant CT-IO (n=219) was 0.86 (ns)[1].
- Quality of Life (QoL) and time to worsening ECOG Performance Status (PS) were compared between groups.

Methods:

- **QoL by EORTC QLQ-C30/LC13** questionnaires and **ECOG PS** were collected at baseline and before each treatment administration until the end of treatment (EOT).
- **Changes in QLQ-C30/LC13 scores from baseline to EoT** were assessed using mixed-effects model for repeated measures (MMRM).
- **Time to worsening ECOG PS** was defined by the time from randomization to the earliest time **when the ECOG becomes > 1 using Kapan Meier method.**

Results:

Figure 1 Time to worsening ECOG PS > 1



- Median time to worsening of ECOG PS was **prolonged in OSE2101 arm with a difference of 5.3 months (p<0.01) compared to SoC in PoI (figure 1).** Increase in ITT was of 3.3 months (p=0.02).

In advanced HLA-A2+ **NSCLC** patients with **IO Secondary Resistance, cancer vaccine OSE2101 significantly increased OS, QoL and Time to worsening of ECOG PS** compared to chemotherapy.

SCAN ME

We thank all investigators and their study team, all patients and their families

Author Contact: benjamin.besse@gustaveroussy.fr

Reference: 1. B Besse et al; #47LBA ESMO 2021 in Annals of Oncology (2021) 32 (suppl_5): S1283-S1346. 0.1016/annonc/annonc741

We thank P. Attali (MD) for his support in writing the abstract and J. Le Boulicaut, C. Hayem and F. Montestruc (eXYSTAT) for the QoL analysis

95 (80.5%) of patients filled questionnaires at baseline and during treatment.

Figures 2a & 2b QLQ-C30 Functional Score change from Baseline to Cycle 8





Spider fall of Least square mean (LSM) change for each scale and p value for overall treatment effect

- **Global Health Status, Physical and Role functioning remained stable with OSE2101 whereas it deteriorated from the 1st cycle with SoC** in PoI (figure 2); Similar results were observed in ITT.

Figures 3a & 3b Change for Symptoms from Baseline to Cycle 8 QLQ-C30/LC13





- **Patients presented fewer symptoms typically related to adverse effects of chemotherapy** (alopecia, mouth soreness, dysphagia, peripheral neuropathy) **with OSE2101** than with SoC.
- **Patient Reported Outcomes together with prior reported lower incidence of severe adverse events[1] confirm that OSE2101 is better tolerated than SoC.**